Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
National Institutes of Health · Opportunity RFA-HL-26-016
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities
- Native American tribal organizations (other)
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
About this opportunity
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Enabling Technologies and Transformative Platforms initiative will support needed to rigorously validate transformative, multi-use platforms or technologies that can enable. Well-suited applications must offer the potential to significantly accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, behavior, prevention or epidemiology. Proposed platforms and technologies may have widespread applicability but must be able to improve the outlook for HLBS-related diseases and disorders.
Award history — this exact opportunity
NIH RePORTER lists 3 funded awards under RFA-HL-26-016 across 3 organizations.
Total award obligations, not per-year amounts.
Recent awardees include: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, STANFORD UNIVERSITY, 3D BIOANALYTIX, INC..
Source: NIH RePORTER, matched on the exact opportunity number. NIH publishes success rates by institute and activity code — source.
Don't want to hunt for grants like this one? Get free deadline alerts for your state and focus areas.
Consultant or grant writer? See the client-ready Opportunity Brief for this grant — actual award sizes vs. the advertised ceiling, who wins, printable "prepared for your client" version.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| NIH Director’s Pioneer Award (DP1 Clinical Trial Optional) | National Institutes of Health | September 9, 2026 0d left | $700k | Nonprofits |
| Fiscal Year 2027 Expanding Nutrition Services | Health Resources and Services Administration | September 9, 2026 0d left | $350k | |
| NIH Director’s Early Independence Award (DP5 Clinical Trial Optional) | National Institutes of Health | September 10, 2026 1d left | $350k | Nonprofits |
| Improving the Capacity of Tribal Communities to Identify Emerging Drug Threats | Office of National Drug Control Policy | September 13, 2026 4d left | $300k | Nonprofits |